Dexamethasone increases blood glucose levels in diabetics

Article

The use of dexamethasone eye drops following cataract surgery has a greater effect on the blood glucose profile of diabetic subjects than in diabetic subjects treated with diclofenac.

The use of dexamethasone eye drops following cataract surgery has a greater effect on the blood glucose profile of diabetic subjects than in diabetic subjects treated with diclofenac, according to the results of a study published in the September issue of Current Eye Research.

Irit Bahar and colleagues from the Sackler Faculty of Medicine at Tel Aviv University, Israel, randomized 285 patients undergoing cataract surgery to receive treatment with topical dexamethasone or diclofenac for one month. Capillary blood samples were collected prior to surgery, immediately following surgery and one week and one month postoperatively.

The researchers noted a significant increase in blood glucose levels in the diabetic dexamethasone group; 170±55.5 mg/dl preoperatively to 229±76.8 mg-dl one month postoperatively. These levels were significantly higher than those found in the diabetic patients treated with diclofenac drops (p=0.038).

It was the conclusion of the authors that dexamethasone eye drops can induce higher levels of blood glucose in diabetic patients than in those treated with diclofenac.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.